Literature DB >> 15708692

Migraine headache relief after transcatheter closure of patent foramen ovale.

Mark Reisman1, Ryan D Christofferson, Jill Jesurum, John V Olsen, Merrill P Spencer, Kimberly A Krabill, Lance Diehl, Sheena Aurora, William A Gray.   

Abstract

OBJECTIVES: The purpose of this study was to determine the effects of transcatheter patent foramen ovale (PFO) closure on migraine frequency in patients with paradoxical cerebral embolism.
BACKGROUND: The prevalence of migraine headache is higher in cryptogenic stroke patients with PFO than in the general population. Previous studies have suggested that closure of the PFO may reduce migrainous symptoms.
METHODS: Between April 2001 and December 2003, 162 consecutive patients with paradoxical cerebral embolism underwent transcatheter PFO closure for prevention of recurrent cryptogenic stroke or transient ischemic attack. A one-year retrospective analysis of migraine symptoms before and after PFO closure was performed.
RESULTS: Active migraine was present in 35% (57 of 162) of patients, and 68% (39 of 57) experienced migrainous aura; 50 patients were available for analysis at one year. Complete resolution of migraine symptoms occurred in 56% (28 of 50) of patients, and 14% (7 of 50) of patients reported a significant (>or=50%) reduction in migraine frequency. Patients reported an 80% reduction in the mean number of migraine episodes per month after PFO closure (6.8 +/- 9.6 before closure vs. 1.4 +/- 3.4 after closure, p < 0.001). Results were independent of completeness of PFO closure at one year.
CONCLUSIONS: In patients with paradoxical cerebral embolism, migraine headaches are more frequent than in the general population, and transcatheter closure of the PFO results in complete resolution or marked reduction in frequency of migraine headache.

Entities:  

Mesh:

Year:  2005        PMID: 15708692     DOI: 10.1016/j.jacc.2004.10.055

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  Patent foramen ovale and migraine: association, causation, and implications of clinical trials.

Authors:  Stewart J Tepper; Catalina Cleves; Frederick R Taylor
Journal:  Curr Pain Headache Rep       Date:  2009-06

Review 2.  Migraine and patent foramen ovale.

Authors:  Jessica Ailani
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

3.  Migraine with aura and persistent foramen ovale.

Authors:  P T Wilmshurst
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

Review 4.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

Review 5.  The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease.

Authors:  Mingming Ning; Eng H Lo; Pei-Chen Ning; Su-Yu Xu; David McMullin; Zareh Demirjian; Ignacio Inglessis; G William Dec; Igor Palacios; Ferdinando S Buonanno
Journal:  Pharmacol Ther       Date:  2013-03-23       Impact factor: 12.310

6.  Patent foramen ovale and migraine: no reason to intervene.

Authors:  Hans-Christoph Diener
Journal:  J Headache Pain       Date:  2007-02       Impact factor: 7.277

7.  Patent foramen ovale closure.

Authors:  Zahid Amin
Journal:  Ann Pediatr Cardiol       Date:  2010-01

Review 8.  The migraine association with cardiac anomalies, cardiovascular disease, and stroke.

Authors:  Todd J Schwedt
Journal:  Neurol Clin       Date:  2009-05       Impact factor: 3.806

9.  Clinical evaluation of a novel occluder device (Occlutech) for percutaneous transcatheter closure of patent foramen ovale (PFO).

Authors:  Florian Krizanic; Horst Sievert; Dietrich Pfeiffer; Thomas Konorza; Markus Ferrari; Hans-Reiner Figulla
Journal:  Clin Res Cardiol       Date:  2008-08-11       Impact factor: 5.460

10.  Stroke and migraine.

Authors:  Jesse Weinberger
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.